Fig. 5

(A) Distance moved (in millimeters) of mutants (irf2bpl^−/−) and wild-type sibling controls (irf2bpl^+/+) measured at 7 d.p.f. in a locomotor assay. During the assay, test animals were first habituated for 30 min, followed by five light-dark cycles for a total of 30 min (n = 36 and 47 for irf2bpl^+/+and irf2bpl^−/− animals, respectively). (B) Representative Western blot and quantification of Wnt1 protein expression in irf2bpl^−/− brain compared to irf2bpl^+/+ controls (n = 3 per group). (C) Analyses of lef1 transcript expression real-time qPCR in irf2bpl^−/− treated with DMSO, SSTC3, or XAV-939, compared to irf2bpl^+/+ treated with DMSO (n = 8 per group). (D and E) Treatment with SSTC3 significantly improved the irf2bpl^−/− mutants’ bout activity when transitioning from a light to dark condition, compared to mutants treated with DMSO (n = 22 and 24 for DMSO-treated irf2bpl^+/+ and irf2bpl^−/− animals; 25 and 23 for SSTC3-treated irf2bpl^+/+ and irf2bpl^−/−, respectively). (F and G) Similar to SSTC3, treatment with XAV-939 significantly improved the mutants’ bout activity compared to DMSO-treated mutants (n = 21 and 19 for DMSO-treated irf2bpl^+/+ and irf2bpl^−/− animals; 36 and 45 for XAV-939–treated irf2bpl^+/+ and irf2bpl^−/− animals, respectively). Results are means ± SEM (*P < 0.05, **P < 0.001, and ****P < 0.0001).